---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-22-000245"
form_type: "8-K"
ticker: "UTMD"
cik: "0000706698"
company_name: "UTAH MEDICAL PRODUCTS INC"
filed_at: "2022-02-02T23:59:59+00:00"
generated_at: "2026-06-27T12:36:32.398653+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# UTMD Q4 EPS $1.127; FY2021 sales $49.1M, net income up 37% YoY

## Summary
- Diluted EPS Q4 $1.127 (up 20.6% YoY); FY GAAP EPS $4.041, non-GAAP $4.147.
- Full year revenue $49.1M (+16%); gross margin expanded to 63.0% from 60.6%.
- Operating income margin 38.5% vs 32.5%; adjusted EBITDA $26.5M (54.1% of sales).
- Paid $2.00/share special dividend in Dec 2021 ($7.3M) plus regular $0.285; cash $60.9M.
- Management projects 2022 adjusted EBITDA ~$30M, up from prior estimate of $28M.

## SEC filing metadata
- accession: 0001096906-22-000245
- form_type: 8-K
- ticker: UTMD
- cik: 0000706698
- company_name: UTAH MEDICAL PRODUCTS INC
- filed_at: 2022-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 99.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/706698/000109690622000245/0001096906-22-000245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/706698/000109690622000245/utmd-20220201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-22-000245
- JSON: https://secwatch.observer/filing/0001096906-22-000245.json
- Plain text: https://secwatch.observer/filing/0001096906-22-000245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.